Success Metrics

Clinical Success Rate
33.3%

Based on 2 completed trials

Completion Rate
33%(2/6)
Active Trials
0(0%)
Results Posted
250%(5 trials)
Terminated
4(67%)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(4)

Detailed Status

Terminated4
Completed2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

completed233%
terminated467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

NCT02535416
terminatedphase_2

A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

NCT02065336
terminatedphase_2

Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

NCT02577029
terminatedphase_2

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

NCT02604212
completedphase_1

Safety and Tolerability Study of ARC-520 in Healthy Volunteers

NCT01872065
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02535416Phase 1

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

Completed
NCT02065336Phase 2

A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Terminated
NCT02577029Phase 2

Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

Terminated
NCT02604212Phase 2

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

Terminated
NCT01872065Phase 1

Safety and Tolerability Study of ARC-520 in Healthy Volunteers

Completed
NCT02452528Phase 2

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6